2010 - Review: Probiotics improve symptoms in adults with the irritable bowel syndrome

van Zanten, Sander Veldhuyzen
September 2010
ACP Journal Club;9/21/2010, Vol. 153 Issue 3, p6
Academic Journal
The article presents a study tracing the effectiveness of probiotics in the treatment of irritable bowel syndrome (IBS). According to meta-analysis by P. Moayyedi and colleagues use of probiotics including Lactobacillus, Bifidobacterium and Streptococcus reduce symptoms of IBS in adults. A comparison chart depicting outcomes for probiotics and placebo in the treatment of IBS, is also presented.


Related Articles

  • Probiotics, with special emphasis on their role in the management of irritable bowel syndrome. Stevenson, Cheryl; Blaauw, RenĂ©e // South African Pharmaceutical Journal;Oct2012, Vol. 79 Issue 9, p42 

    Probiotics are live microorganisms, and when administered in adequate amounts, bestow beneficial effects on the host. The therapeutic and preventative application of probiotics in several disorders is receiving increasing attention, and this is especially true when gastrointestinal microbiota...

  • Treatment of irritable bowel syndrome. Thomas, Jack // Australian Journal of Pharmacy;Apr2009, Vol. 90 Issue 1067, p74 

    The article offers information concerning the findings on a study of ways on treating irritable bowel syndrome. It suggests that fiber and peppermint oil which has been shown to have antispasmodic properties has been used in the treatment of irritable bowel syndrome. It notes that probiotics may...

  • Meta-analysis of probiotics for the treatment of irritable bowel syndrome. McFarland, Lynne V.; Dublin, Sascha; Costa, Francesco; Vandenplas, Yvan // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2650 

    Irritable bowel syndrome (IBS) is a chronic condition affecting 3%-25% of the general population. As no curative treatment is available, therapy is aimed at reducing symptoms, often with little success. Because alteration of the normal intestinal microflora has been observed in IBS, probiotics...

  • Salix's Phase III Bowel Drug Shows Sustained Relief of IBS. Hollingsworth, Catherine // BioWorld Today;5/5/2010, Vol. 21 Issue 86, p1 

    The article reports on the results of the Phase III studies of Xifaxan/rifaximin from Salix Pharmaceuticals showing that the drug provided acute and sustained relief from nonconstipation irritable bowel syndrome (non-C IBS) symptoms. The conduct of the 14-day course of Xifaxan 550 milligrams...

  • Probiotic Ingredient Improves Digestive Health. Kiefer, Dale // Life Extension;Aug2009, Vol. 15 Issue 8, p21 

    The article reports on a study which states that Bacillus coagulan, a strain of probiotic, lessens bloating in abdominal disease patients and reduces symptoms of abdominal pain. The study which was published earlier in journals including "Postgraudate Medicine," revealed that Bacillus coagulan...

  • Understanding the role of probiotics in supporting digestive comfort. Gage, Joycelyn // Nursing Standard;9/30/2009, Vol. 24 Issue 4, p47 

    Many people experience digestive discomfort at some time in their lives. It affects those who are healthy and unhealthy, and in some cases can signal a more serious underlying condition. For most people the discomfort is minor and transitory, but for some it can cause regular unpleasant...

  • RESEARCH CAPSULE.  // Functional Ingredients;Oct2011, Issue 112, p50 

    The article presents abstracts of the articles "Kidney Function in Metabolic Syndrome May be Improved With Pycnogenol," by S. Stuard and "Probiotic Bacteria: Probiotic Bacteria Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis Bi- 07 Versus Placebo for the Symptoms of Bloating in...

  • Management of irritable bowel syndrome. Gunn, M.C.; Cavin, A.A.; Mansfield, J.C. // Postgraduate Medical Journal;Mar2003, Vol. 79 Issue 929, p154 

    The management of IBS involves a positive approach with establishment of a relationship with the patient from the initial consultation. Diagnosis is predominantly clinical, with exclusion of pathology using the minimum of investigations, targeted according to the age and alarm symptoms....

  • New Drugs in the Management of the Irritable Bowel Syndrome. Farthing, M.J.G. // Drugs;Jul1998, Vol. 56 Issue 1, p11 

    Irritable bowel syndrome (IBS) continues to provide a major therapeutic challenge to clinicians and those involved in drug development. It seems unlikely from the data before us that this multisymptom syndrome with peripheral and central components is likely to respond reliably in all patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics